IDEXX Laboratories (IDXX) Stock Price, News & Analysis

Company Overview

IDEXX Laboratories, Inc., founded in 1983 and headquartered in Westbrook, Maine, is a leading provider of diagnostic and information technology-based products and services for the animal health, water testing and dairy markets. Originally established to develop rapid diagnostic tests for companion animals, the company has expanded its portfolio through both innovation and strategic acquisitions. Over the decades, IDEXX has grown into a diversified life sciences company, leveraging proprietary technologies to deliver actionable insights to its customers.

In the animal health segment, IDEXX offers a comprehensive suite of in-clinic diagnostic instruments, consumables and digital imaging solutions. Key products include the SNAP® family of rapid immunoassays, Catalyst® chemistry analyzers, ProCyte® hematology systems and sophisticated imaging equipment that enable veterinarians to perform a wide range of tests—from routine blood panels and disease screening to advanced imaging for soft tissue and orthopedic evaluation. The company also provides practice management software and telehealth services designed to streamline clinic operations and enhance patient care.

Beyond veterinary diagnostics, IDEXX serves the water quality and dairy industries. Its water microbiology business offers reagents, instruments and data management tools to detect pathogens and monitor water safety in municipal, recreational and industrial settings. In the dairy sector, IDEXX supplies tests for mastitis detection, antibiotics screening and herd health monitoring, helping producers maintain milk quality and comply with regulatory standards. The company’s emphasis on rapid, accurate results supports public health initiatives and food safety programs worldwide.

With operations in more than 175 countries, IDEXX maintains a global network of R&D centers, manufacturing facilities and distribution channels. The company is led by President and Chief Executive Officer Jonathan W. Ayers, who has overseen continued investment in innovation, expanded service offerings and international growth since 2018. Under his leadership, IDEXX remains focused on delivering cutting-edge diagnostics and data-driven solutions that empower customers to make timely, informed decisions.

Key Stats

• Today's Range: $527.88 to $538.92
• 50-Day Range: $473.71 to $546.31
• 52-Week Range: $356.14 to $549.52
• Volume: 348,343 shs
• Average Volume: 647,366 shs
• Market Capitalization: $42.89 billion
• P/E Ratio: 49.29
• Dividend Yield: N/A
• Price Target: $558.11
• Consensus Rating: Moderate Buy

IDEXX Laboratories Stock Analysis - MarketRank™

IDEXX Laboratories scored higher than 71% of companies evaluated by MarketBeat, and ranked 269th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

IDEXX Laboratories has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.83%

Earnings Growth

Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEXX Laboratories is 49.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEXX Laboratories is 49.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.13.

Price to Earnings Growth Ratio

IDEXX Laboratories has a PEG Ratio of 3.95. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IDEXX Laboratories has a P/B Ratio of 27.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.20% of the float of IDEXX Laboratories has been sold short.

Short Interest Ratio / Days to Cover

IDEXX Laboratories has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IDEXX Laboratories has recently increased by 0.39%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEXX Laboratories does not currently pay a dividend.

Dividend Growth

IDEXX Laboratories does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -2.09

Percentage of Shares Shorted

3.20% of the float of IDEXX Laboratories has been sold short.

Short Interest Ratio / Days to Cover

IDEXX Laboratories has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IDEXX Laboratories has recently increased by 0.39%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.04

News Sentiment

IDEXX Laboratories has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for IDEXX Laboratories this week, compared to 18 articles on an average week.

Search Interest

5 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

2 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,182,920.00 in company stock.

Percentage Held by Insiders

Only 0.98% of the stock of IDEXX Laboratories is held by insiders.

Percentage Held by Institutions

87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IDXX Stock Analysis - Frequently Asked Questions

How have IDXX shares performed this year?

IDEXX Laboratories' stock was trading at $413.44 at the beginning of 2025. Since then, IDXX stock has increased by 29.0% and is now trading at $533.37.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Thursday, May, 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The company's revenue for the quarter was up 3.6% on a year-over-year basis.
Read the conference call transcript.

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' top institutional shareholders include Seilern Investment Management Ltd (0.26%), Mogy Joel R Investment Counsel Inc. (0.11%), Assenagon Asset Management S.A. (0.08%) and Westwind Capital (0.06%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, James F Polewaczyk, George Fennell, Kathy V Turner, Michael Lane, Daniel M Junius, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/12/2025
• Next Earnings (Confirmed): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:IDXX
• CIK: 874716
• Web: www.idexx.com
• Phone: (207) 556-0300
• Fax: 207-556-4346
• Employees: 11,000
• Year Founded: 1983

Price Target and Rating

• Average Price Target for IDEXX Laboratories: $558.11
• High Price Target: $625.00
• Low Price Target: $510.00
• Potential Upside/Downside: +4.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.82
• Trailing P/E Ratio: 49.29
• Forward P/E Ratio: 44.71
• P/E Growth: 3.95
• Net Income: $887.87 million
• Net Margins: 22.76%
• Pretax Margin: 28.60%
• Return on Equity: 57.35%
• Return on Assets: 26.97%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 1.16
• Quick Ratio: 0.81

Sales & Book Value

• Annual Sales: $3.90 billion
• Price / Sales: 11.01
• Cash Flow: $12.25 per share
• Price / Cash Flow: 43.53
• Book Value: $19.48 per share
• Price / Book: 27.38

Miscellaneous

• Outstanding Shares: 80,420,000
• Free Float: 79,634,000
• Market Cap: $42.89 billion
• Optionable: Optionable
• Beta: 1.54